Clinical Lymphoma Myeloma & Leukemia

Papers
(The H4-Index of Clinical Lymphoma Myeloma & Leukemia is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
SOHO State of the Art Updates and Next Questions | Approach to BCR::ABL1-Like Acute Lymphoblastic Leukemia74
Corrigendum to “OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no 37
P-112 Fall Risk Assessment and Fall Prevention in Patients With Multiple Myeloma: First Results of the MYFALL-Trial36
P-186 Identifying a New Risk-Stratification Strategy by Including Single-Cell Biomarkers in Multiple Myeloma35
P-154 Multidisciplinary, Patient-Centric Bone Disease Management in Multiple Myeloma – a Single-Centre Experience35
P-202 Risk Factors Predicting Early Relapse for Newly Diagnosed Multiple Myeloma Patients Treated with Front-Line VRD Regimen31
P-330 Stem Cell Mobilization Strategy With Pegilgrastim for Stem Cell Transplantation for Multiple Myeloma: A Direct Cost Comparison30
P-309 Diagnostic Challenges in Systemic Amyloidosis: Exploring the Impact of Mass Spectrometry in a Middle-Income Country Cohort28
P-232 Comprehensive Genomic Sequencing Predicts Sub-Optimal Response to Bispecific Antibodies (BsAb) and Chimeric Antigen Receptor T Cells (CAR-T) in Multiple Myeloma (MM)27
P-342 Impact of Achieving <VGPR With Dara-RVD Induction Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients26
P-068 Developing Novel DKK1-A2 CAR-T Cell Therapy for Myeloma and Other Hematologic Malignancies25
P-012 Real-World Safety and Early Efficacy of Talquetamab in Patients with Heavily-Pretreated Relapsed/Refractory Multiple Myeloma25
OA-27 Para-Medullary (PMD) and Extra-Medullary (EMD) Myeloma Demonstrate Increased Copy Number Aberration, Mutational Burden, Structural Variants and Genomic Complexity Compared to Marrow-Based Myelom25
P-113 An Artificial Intelligence-Based 3D-Segmentation Assessment of Sarcopenia Utilizing Whole-Body Computed Tomography in Patients With Multiple Myeloma24
P-100 Prevalence of monoclonal gammopathies in adult Uruguayan population23
P-455 Survey of multiple myeloma (MM) patients and healthcare professionals (HCPs) on the relevance of existing health quality-of-life (QoL) questionnaires (QoLQ) to real-world QoL issues of MM patien23
P-139 Impact of melphalan staggered dosing prior to autologous hematopoietic cell transplantation for multiple myeloma patients21
OA-38 Physical activity interventions to improve functional performance in patients with multiple myeloma21
Management Challenges in Patients with Treatment-Free Remission of Chronic Myeloid Leukemia20
Demographic Characteristics of Hospitalized Patients With History of Multiple Myeloma in Remission: Insights From National Inpatient Sample 202120
MM-731 Prognostic Implications of Immune Paralysis in Newly Diagnosed Multiple Myeloma20
MPN-153 A Phase 1b Trial of DISC-0974, an Antihemojuvelin Antibody, in Participants With Myelofibrosis and Anemia20
0.24967002868652